Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Research in Pediatrics & Neonatology

Diagnosis of Acquired Hemophilia A Must be Considered in Childhood: A Case Report

  • Open or CloseHarroche A1*, Lasne D2,3, Bally C1, Pascreau T2,3, Rothschild R1 and Borgel D2,3

    1 Hemophilia Care Center, Hematology Unit, Hôpital Universitaire Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris, France.

    2Service dHématologie Biologique, Hôpital Universitaire Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris, France.

    3UMR INSERM 1176, Hôpital Bicêtre, Le Kremlin-Bicêtre, France

    *Corresponding author: Harroche Annie, Centre de traitement de l’Hémophilie, Service d’Hématologie Clinique, Hôpital Necker, France

Submission: November 11, 20199; Published: December 02, 2019

ISSN : 2576-9200
Volume4 Issue1

Abstract

Acquired Hemophilia A is a very rare disease in children but may be life-threatening. We report the case of a 5-year-old child, without any bleeding history. He presented a severe bleeding episode after a circumcision. The blood loss was important, with a hemoglobin rate at 54g/L, requiring a transfusion. The first biological assessment of hemostasis lead to the suspected diagnosis of congenital hemophilia (FVIII=4%), but factor VIII infusions were inefficient. Identification of a specific inhibitor against factor VIII rectified the diagnosis: it was an acquired hemophilia A. No underlying infectious, autoimmune or neoplastic disease was found. Interestingly, he has family history of immune disease: his brother has a juvenile arthritis and his father a Sjogren syndrome.

Clinical evolution was favorable after treatment by recombinant activated factor VII (Novoseven®). Afterwards, he has two bleeding episodes: a large post-venous puncture hematoma, and a post-traumatic hemarthrosis of the knee, efficiently treated by Novoseven®. An immunosuppressive treatment started then: he received a first line therapy of corticoids without any effect on the inhibitor level. A second line therapy with rituximab was attempted, with a greater efficacy. The inhibitor level is now below 1 BU/ml, and the factor VIII level is 120%. This case highlights the difficulties of diagnosing acquired hemophilia A in childhood. Due to its rarity, this condition was first not recognized. Concerning immunosuppressive therapy, this case is the second case of the pediatric literature in this indication that proves efficacy of rituximab.

Keywords: Acquired hemophilia A; Childhood; Rituximab; Post-operative hemorrhage; Hemarthrosis; Diagnosis

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137
  • info@crimsonpublishers.com
  • www.crimsonpublishers.com